|View printer-friendly version|
|March 23, 2015 8:48 a.m.|
|Teva’s TEV-48125 Meets Primary and Secondary Endpoints in Episodic Migraine Study, Demonstrating Treatment Concept After a Single Dose|
After recently announced positive results in chronic migraine, TEV-48125 becomes the first treatment to meet efficacy endpoints in trials of both chronic and episodic migraine and across multiple doses
TEV-48125 is a novel investigational anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, and these data, together with the recent results achieved in the difficult to treat chronic migraine setting, make this the first therapy to successfully meet efficacy endpoints in the prevention of both chronic and episodic migraine, and at multiple doses, in advanced clinical trials.
Initial analysis of results demonstrated that both doses of TEV-48125 met primary and secondary endpoints achieving significant reductions in mean monthly migraine days and monthly headache days relative to baseline. These are considered as validated endpoints to assess benefits of new migraine treatments.
Additionally, a single administration of both tested doses of TEV-48125 resulted in a statistically significant separation from placebo. Data confirm that treatment with TEV-48125 resulted in separation for both primary and secondary endpoints, at all months of therapy, in both the chronic and episodic migraine clinical trials.
Furthermore, these results were achieved in the presence of patients being allowed to remain on existing migraine prevention therapy, and without limitation on the amount of acute migraine treatment used. This was an attribute of the TEV-48125 phase IIb studies not seen in other reported anti-CGRP studies, and the results demonstrated separation in favor of TEV-48125 even in patients considered to be on optimal current therapy. Overall, four different doses across two indications studied in a total of 561 patients met all study endpoints establishing clinical proof of concept for anti-CGRP ligand therapy.
“The collective data from this phase II program have validated the
concept of targeting the anti-CGRP ligand with TEV-48125 with a level of
confidence that we did not foresee. We now have reason to believe that
we have developed an approach that gives us the foundation, with
identified doses, to progress to a Phase III program that we hope will
take TEV-48125 a step closer to potentially making a significant
difference to patients’ lives” stated Marcelo E. Bigal, Teva’s Head of
The study compared two active arms of high and low dose TEV-48125, administered as a subcutaneous injection, once a month for three months, against placebo. In this study no important safety or tolerability concerns were identified. The adverse event profile for TEV-48125 appeared similar to placebo for most parameters and supportive of previous Phase I and II safety data. Of the adverse events reported, mild, transient injection site discomfort and redness was infrequent but higher than that observed in the placebo group. No serious treatment-related serious adverse events were seen.
"Migraine is a truly debilitating disorder. Up to 15% of the global
population is affected by migraine. It causes highly disabling pain and
other symptoms that disrupt the life of the patient and their families,"
Full results from the study will be presented at a forthcoming scientific meeting and will be submitted to a peer-reviewed journal for publication.
About the HFEM Study
The study was a multicenter, randomized, double-blind, placebo-controlled, parallel-group, study comparing the efficacy and safety of two doses of subcutaneous TEV -48125 with placebo for the preventive treatment of high frequency episodic migraine in 297 patients.
Multiple doses were selected for testing to define dose-response and allow selection of doses for a Phase 3 study.
Treatment was administered once every 28 days (i.e.; once monthly) over
a 3-month period. 300 patients were enrolled and randomized to one of
three treatment arms receiving high dose TEV-48125, low dose TEV-48125
or placebo, administered subcutaneously once a month. The study was
conducted in approximately 60 centers in the
TEV -48125 (formerly LBR-101/ RN-307) is a monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), a well-validated target in migraine. CGRP signaling may be disrupted by targeting the ligand itself or its receptor.
Teva's approach targets the ligand, allowing for some CGRP signaling
during therapy, which may avoid the potential, unknown, effects of a
long-term total disruption to the normal physiological functions of the
CGRP system. TEV-48125 is being developed for two distinct migraine
indications; chronic migraine and high frequency episodic migraine.
Positive results from the Phase IIb chronic migraine study were
TEV-48125 successfully completed five Phase I trials with 94 healthy
volunteers. Results were published
in Cephalalgia, the official journal of the
Global prevalence of migraine is estimated to be almost 15%. Migraine
was ranked seventh highest among specific causes of disability globally,
responsible for 2.9% of all Years Lost to Disability (YLDs). Migraine
is, by a wide margin, the leading cause of disability among neurological
disorders, accounting for over half of all YLDs attributed to these (J
Headache Pain. 2013; 14(1): (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606966/).
Approximately 3.2 million Americans, mostly women, suffer from Chronic Migraine. Chronic migraine is characterized by headaches on at least 15 days per month. Chronic migraine patients are often referred to as the ‘invisible population’ due to the isolating nature of the condition, where patients are left, in many cases, effectively house-bound.
Chronic migraine imposes a considerable burden on patients, magnified by the paucity of approved treatment options for this condition. More than one in four of all migraineurs are candidates for preventive therapy, and a substantial proportion of those who might benefit from prevention do not receive it. Consequently, the prophylactic treatment of chronic migraine continues to present considerable challenges, and there remains a significant medical need for new, safe and effective migraine prophylaxis options.
Episodic Migraine impacts up to 14% of the population, and approximately 20% of women, globally. High frequency episodic migraine substantially impacts the individual, their family, and society. Episodic migraine is the most common neurological condition, more prevalent than diabetes, epilepsy and asthma combined.
Teva's Safe Harbor Statement under the
This release contains forward-looking statements, which are based on
management’s current beliefs and expectations and involve a number of
known and unknown risks and uncertainties that could cause our future
results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products;
competition for our innovative products, especially Copaxone®
(including competition from orally-administered alternatives, as well as
from potential purported generic equivalents) and our ability to
migrate users to our 40 mg/mL version; the possibility of material
fines, penalties and other sanctions and other adverse consequences
arising out of our ongoing FCPA investigations and related matters; our
ability to achieve expected results from the research and development
efforts invested in our pipeline of specialty and other products; our
ability to reduce operating expenses to the extent and during the
timeframe intended by our cost reduction program; our ability to
identify and successfully bid for suitable acquisition targets or
licensing opportunities, or to consummate and integrate acquisitions;
the extent to which any manufacturing or quality control problems damage
our reputation for quality production and require costly remediation;
increased government scrutiny in both the U.S. and